Ignite Creation Date:
2025-12-24 @ 12:50 PM
Ignite Modification Date:
2026-01-17 @ 3:52 AM
Study NCT ID:
NCT00566761
Status:
TERMINATED
Last Update Posted:
2024-05-30
First Post:
2007-11-30
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO
Sponsor:
Asociación para Evitar la Ceguera en México
Organization:
Study Overview
Official Title:
Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion
Status:
TERMINATED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
undefined
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MECROV
Brief Summary:
Treatment of macular edema secondary to central retinal vein occlusion is more effective with combined therapy of bevacizumab and triamcinolone than bevacizumab alone.
Detailed Description:
Comparison of two groups with different treatment with registrations of outcome in BCVA and complications
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: